Real world clinical performance of the zotarolimus eluting coronary stent system in Chinese patients: a prospective, multicenter registry study

Early clinical trials with the Endeavor zotarolimus eluting stent (ZES) in western populations demonstrated low rates of target lesion revascularization with a favorable safety profile including low late stent thrombosis with up to 5 years of follow-up. The aim of this clinical registry study was to evaluate real world clinical performance of the ZES coronary system in Chinese patients.

2016

08-12

Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery

We aimed to investigate short-term outcomes of the XINSOEB bioresorbable sirolimus-eluting scaffold in human coronary artery.

2016

08-12

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

2015

08-04

Outcomes with bioabsorbable vascular scaffolds versus everolimus-eluting stents Insights from randomized trials

Bioresorbable vascular scaffolds (BVS) have been shown to be non-inferior to second generation drug eluting stents in recent clinical trials. However, the trials were not powered for individual endpoints and there is concern for increased device thrombosis with BVS.

2015

08-04

Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled

Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease treated with percutaneous revascularisation.

2015

08-04

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimuseluting metallic stents in patients with coronary artery disease: ABSORB Japan

superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown.

2015

08-03

< 12 > 前往 頁

公司信息

北京飛渡醫療器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

 

聯系我們

地址：北京市大(dà)興區(qū)永旺西路26号院中關村醫(yī)療器(qì)械園11号樓

電(diàn)話(huà)：010-6297-7955             郵箱：amt@ametcorp.com

圖片名稱

微信聯系

@Copyright 2022 北京飛渡醫療器械有限公司 All rights reserved   版權所有(yǒu)

京ICP備11028039号    網站(zhàn)建設：中企動力  南京